Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 24, 2002

View Archived Issues

Vitamin C conjugates improve entry of CNS drugs into the brain

KB-130015: a potential antiarrhythmic agent with an improved safety profile compared to amiodarone

Millennium reports significant progress during 2001

Signature to acquire PrimeCyte

Enrollment completed in hysterectomy arm of phase II trial in uterine fibroids

Introgen receives grant to evaluate INGN-241 in melanoma

OP-2000 granted new generic name by USAN

Allergan and EntreMed enter five-year strategic alliance in eye diseases

Appetite suppression with C-75 associated with alterations in balance of hypothalamic neuropeptides

Orfadin approved for treatment of hereditary tyrosinemia type I

Altea receives grant for MicroPor delivery of insulin

Phytomedics and Degussa BioActives to codevelop PMI-5011

Modafinil receives approval in Mexico

Progen enrolls first patient in phase II trial of PI-88 in multiple myeloma

Pfizer describes series of hygromycin A derivatives

Lactams that inhibit Abeta formation with potential in Alzheimer's disease

Short-course therapy with Zithromax approved for otitis media

Amino-substituted carbothioic acid esters that act as apoptosis inducers

Chugai discloses new series of vitamin D derivatives and their use

Compounds with thrombopoietin-like activity tested at Chugai

Excitatory amino acid modulators patented by Lilly

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...